Faeth Therapeutics, Inc.
- FTH
- NASDAQ
- Biotechnology
- Cancer Therapeutics
- Clinical-Stage Biotech
$18.80
Today −8.74%Quote Oct 16, 2026, 08:00 PM UTC
−46.48%over the last month
Max drawdown −46.5%From 1-month high −46.5%3 months −33.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$484.6M
Quote Oct 16
Next earnings
Nov 13
Expected, not confirmed
Analyst target
$58.50
+211.2% from here
Floor
$17.28
8.1% below price
Where the price sits
5 analysts
Analyst range, low to high
$50.00$70.00
- Price $18.80
- Resistance $20.48
- Consensus $58.50
Analysts' average target sits about 211% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about FTHPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
29